HIV protease inhibitors inhibit the development of preerythrocytic-stage Plasmodium parasites

Journal of Infectious Diseases

Volumn 199, Issue 1, 2009, Pages 134-141

  Hobbs, Charlotte V ^a,e   Voza, Tatiana ^b   Coppi, Alida ^b   Kirmse, Brian ^c   Marsh, Kennan ^d   Borkowsky, William ^a   Sinnis, Photini ^b  

^a Saul Krugman Department of Pediatric Infectious Disease and Immunology   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ABBOTT LABORATORIES   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

AFRICA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; ERYTHROCYTE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIFE CYCLE; LIVER CELL; MALARIA; MOUSE; NONHUMAN; PARASITE DEVELOPMENT; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; SPOROZOITE;

ANIMALS; ANOPHELES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; MALARIA; MICE; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM YOELII; PYRIMIDINONES; RITONAVIR;

EID: 58749093761     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/594369     Document Type: Article

References (49)

1. Snow RW, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's nonpregnant population. Bull World Health Organ 1999; 77:624-40.
2. World Health Organization. Malaria and HIV interactions and their implications for public health policy. Available at: http://www.who.int/malaria/ malaria-HIV/MalariaHIVinteractions-report.pdf. Accessed 4 December 2007.
3. Korenromp EL, Williams BG, de Vlas SJ, et al. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis 2005; 11:1410-9.
4. UNAIDS. Report on the global AIDS epidemic. Available at: http://www.unaids.org/en/HIV-data/epi2006. Accessed 15 November 2007.
5. Slutsker L, Marston BJ. HIV and malaria: interactions and implications. Curr Opin Infect Dis 2007; 20:3-10.
6. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233-40.
7. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004; 71(Suppl 2):41-54.
8. Mwapasa V, Rogerson SJ, Molyneux ME, et al. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 2004; 18:1051-9.
9. Abu-Raddad LJ, Patnaik P, Kublin J. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314:1603-6.
10. Shah SN, Smith EE, Obonyo CO, et al. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J Infect Dis 2006; 194:1519-28.
11. Quigley MA, Hewitt K, Mayanja B, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051-6.
12. Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005; 192:984-91.
13. Sinnis P, Coppi A. A long and winding road: the Plasmodium sporozoite's journey in the mammalian host. Parasitol Int 2007; 56:171-8.
14. Mikolajczak SA, Aly AS, Kappe SH. Pre-erythrocytic malaria vaccine development. Curr Opin Infect Dis 2007; 20:461-6.
15. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004; 190:1998-2000.
16. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005; 49:2983-5.
17. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother 2006; 50:639-48.
18. Martins TM, Domingos A, Berry C, Wyatt DM. The activity and inhibition of the food vacuole plasmepsin from the rodent malaria parasite Plasmodium chabaudi. Acta Trop 2006; 97:212-8.
19. Redmond AM, Skinner-Adams T, Andrews KT, et al. Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 2007; 21:763-5.
20. Pillai DR, Rosenthal PJ, DeRisi JL. The antimalarial effect of HIV NRTIs on Plasmodium falciparum [abstract 999]. In: Abstracts of the 55th American Society of Tropical Medicine and Hygiene Conference (Atlanta). Am J Trop Med Hyg 2006; 75(Suppl 5):1-323.
21. Invirase product information. Available at: http://www.rocheusa.com/ products/invirase/pi.pdf. Accessed 4 November 2008.
22. Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 2004; 21:1622-30.
23. Tsuji M, Mattei D, Nussenzweig RS, Eichinger D, Zavala F. Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol Res 1994; 80:16-21.
24. Rénia L, Miltgen F, Charoenvit Y, et al. Malaria sporozoite penetration: a new approach by double staining. J Immunol Methods 1988; 112:201-5.
25. Pinzon-Ortiz C, Friedman J, Esko J, Sinnis P. The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for Plasmodium sporozoite attachment to target cells. J Biol Chem 2001; 276:26784-91.
26. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980; 207:71-3.
27. Khan ZM, Vanderberg JP. Role of host cellular response in differential susceptibility of nonimmunized BALB/c mice to Plasmodium berghei and Plasmodium yoelii sporozoites. Infect Immun 1991; 59:2529-34.
28. Belmonte M, Jones TR, Lu M, et al. The infectivity of Plasmodium yoelii in different strains of mice. J Parasitol 2003; 89:602-3.
29. Bruña-Romero O, Hafalla JC, González-Aseguinolaza G, Sano G, Tsuji M, Zavala F. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 2001; 31:1499-502.
30. Gantt SM, Myung JM, Briones MR, et al. Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother 1998; 42:2731-8.
31. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53:4-9.
32. Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987; 329:351-4.
33. Wu Y, Wang X, Liu X, Wang Y. Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite. Genome Res 2003; 13:601-16.
34. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA 2002; 99:990-5.
35. Bonilla JA, Bonilla TD, Yowell CA, Fujioka H, Dame JB. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol Microbiol 2007; 65:64-75.
36. Parikh S, Liu J, Sijwali P, Gut J, Goldberg DE, Rosenthal PJ. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob Agents Chemother 2006; 50:2207-9.
37. Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2007; 51:759-62.
38. Tarun AS, Peng X, Dumpit RF, et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci USA 2008; 105:305-10.
39. Dame JB, Yowell CA, Omara-Opyene L, Carlton JM, Cooper RA, Li T. Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Mol Biochem Parasitol 2003; 130:1-12.
40. Pozio E, Morales MA. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol 2005; 21:58-63.
41. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336-45.
42. Mahmoudi N, Garcia-Domenech R, Galvez J, et al. New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 2008; 52:1215-20.
43. Carraz M, Jossang A, Franetich JF, et al. A plant-derived morphinan as a novel lead compound active against malaria liver stages. PLoS Med 2006; 3:e513.
44. Neerja J, Puri SK. Plasmodium yoelii: activity of azithromycin in combination with pyrimethamine or sulfadoxine against blood and sporozoite induced infections in Swiss mice. Exp Parasitol 2004; 107:120-4.
45. Singh N, Puri SK. Causal prophylactic activity of antihistaminic agents against Plasmodium yoelii nigeriensis infection in Swiss mice. Acta Trop 1998; 69:255-60.
46. Lindenthal C, Weich N, Chia YS, Heussler V, Klinkert MQ. The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology 2005; 131:37-44.
47. Coppi A, Cabinian M, Mirelman D, Sinnis P. Antimalarial activity of allicin, a biologically active compound from garlic cloves. Antimicrob Agents Chemother 2006; 50:1731-7.
48. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 2005; 201:27-33.
49. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Available at: http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf. Accessed 1 November 2007.